Clincosm LogoSign in Get a demo

Human Phenotype Project Study Protocol

Sponsor
Weizmann Institute of Science (Other)
Overall Status
Recruiting
CT.gov ID
NCT05817734
Collaborator
(none)
30,000
Enrollment
1
Location
327
Anticipated Duration (Months)
91.7
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This is a prospective study aimed at recruiting 30,000 individuals, aged 40-70 years old, and following them longitudinally for 25 years with repeated measurements. The basic follow-up frame will include a visit to the Clinical Test Center (CTC) every two years and a phone interview every other year (on uneven years). Sample collection and biobanking will be performed every two years and online questionnaires will be filled out on an annual basis.

The primary goals are to study the variation observed across different individuals in disease susceptibility, clinical phenotypes, and therapeutic responses. The study aims at studying the complex interplay and relative contribution of different omics, physiological characteristics and lifestyle on disease pathogenesis and progression and to evaluate how these effects are mediated.

Condition or Disease Intervention/Treatment Phase

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    30000 participants
    Observational Model:
    Cohort
    Time Perspective:
    Prospective
    Official Title:
    Longitudinal Collection of Observational Clinical and Lifestyle Data
    Actual Study Start Date :
    Oct 1, 2018
    Anticipated Primary Completion Date :
    Dec 31, 2045
    Anticipated Study Completion Date :
    Dec 31, 2045

    Outcome Measures

    Primary Outcome Measures

    1. Adult disease [25 years]

      Development of medical conditions based on participant's self-reporting coded to ICD11.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • Ages 18+, males and females.
    Exclusion Criteria:

    • Pregnancy.

    • Mentally disabled or in general legally non-competent.

    • Prisoner or soldier. Soldiers: mandatory service only

    • Active cancer

    • Fertility Treatments (current)

    • Hepatitis ( B, C), chronic or acute

    • HIV

    • Liver cirrhosis

    • Dialysis

    • Unstable medical conditions

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Weizmann institute of science Reẖovot Israel

    Sponsors and Collaborators

    • Weizmann Institute of Science

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Eran Segal, Prof. Eran Segal, PI at the department of computer science and applied math, Weizmann Institute of Science
    ClinicalTrials.gov Identifier:
    NCT05817734
    Other Study ID Numbers:
    • 1789-1
    First Posted:
    Apr 18, 2023
    Last Update Posted:
    Apr 18, 2023
    Last Verified:
    Apr 1, 2023
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No

    Study Results

    No Results Posted as of Apr 18, 2023